Bioheart has an exclusive license to patents covering the culturing of myogenic cells such as myoblasts, for the purpose of muscle regeneration. The company's goal is a cell therapy that uses autologous myocytes to replace damaged heart muscle cells, potentially offering a therapy that can reverse the course of congestive heart failure.

M&A was the universal prescription for the medical industry in 1998 as acquisition dollar volumes hit record levels. For some, the dealmaking further separates the haves and have-nots. For others, it's an addictive drug for coping with chronic insufficiency syndrome. But for nearly everyone who's using it, M&A is the easiest, if not always an effective, answer to the increasingly intractable problem of growth.

By focusing on building a better delivery system, Intella hopes to cpature part of the booming stent market.

The first generation less-invasive devices for abdominal aortic aneurysm (AAA) surgery haven't yet been approved and the next generation is already here.